TG Therapeutics increases FY25 revenue forecast to $600M, up from $585M, surpassing consensus of $588.12M.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 03 2025
0mins
- Revenue Target Increase: The U.S. net product revenue target for BRIUMVI has been raised to approximately $585 million for the full year 2025.
- Previous Guidance: The prior guidance for BRIUMVI's revenue was set between $570 million and $575 million for the same period.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 30.310
Low
15.00
Averages
43.50
High
60.00
Current: 30.310
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries
- Price Target Increase: Goldman Sachs raised TG Therapeutics' price target from $37 to $39 while maintaining a 'neutral' rating, indicating over a 32% upside potential, reflecting market optimism regarding the company's future growth prospects.
- Briumvi Market Performance: CEO Michael Weiss stated that Briumvi is now available in 16 countries, with over 20,000 patients prescribed to date, primarily in the U.S., laying a solid foundation for future revenue growth for the company.
- Revenue Expectations: The company anticipates Briumvi's U.S. revenue to range between $825 million and $850 million, which will be a major driver of overall revenue, with a forecast of $875 million to $900 million by 2026, indicating strong market demand.
- Improved Retail Sentiment: According to Stocktwits data, retail sentiment on TG Therapeutics has improved from 'bullish' to 'extremely bullish' over the past month, with message volume surging over 500% in the last week, demonstrating strong investor interest in the stock.
Continue Reading
S&P 500 Index Falls 0.53% as Tech Stocks Weigh Down Market
- Market Weakness: The S&P 500 Index closed down 0.53% and the Nasdaq 100 Index fell 1.07%, indicating that weakness in technology stocks and chip makers negatively impacted the broader market, reflecting investor concerns over rising geopolitical risks.
- Positive Economic Data: U.S. November retail sales rose 0.6% month-over-month, exceeding expectations of 0.5%, while the November Producer Price Index increased 3.0% year-over-year, stronger than the anticipated 2.7%, suggesting a rebound in economic activity that could support the market.
- Rising Oil Prices: WTI crude oil surged to a 2.5-month high amid concerns over the situation in Iran, driving investors towards safe-haven assets, with gold and silver also reaching new highs, indicating increased demand for secure investments.
- Fed Policy Expectations: The market is pricing in a 5% chance of a 25 basis point rate cut at the upcoming FOMC meeting on January 27-28, reflecting a cautious outlook among investors regarding future monetary policy.
Continue Reading